Furosemide Infusion Protocol for 66kg Patient with Brain Mass
For a 66kg patient with an intracranial mass requiring continuous IV furosemide, initiate the infusion at 5-10 mg/hour (maximum 20 mg/hour) after pH adjustment to >5.5, targeting intracranial pressure reduction while monitoring for electrolyte disturbances and renal function. 1
Dosing Strategy
Initial Bolus Consideration
- For acute ICP control: Consider an initial bolus of 40-80 mg IV given slowly over 1-2 minutes 1
- Studies in neurosurgical patients demonstrate that a single 80 mg bolus can reduce ICP by approximately 56% within the operative period 2
- This provides rapid initial ICP reduction before transitioning to continuous infusion
Continuous Infusion Protocol
Preparation requirements 1:
- Add furosemide to Normal Saline, Lactated Ringer's, or D5W only after adjusting pH to >5.5
- Furosemide has a pH of ~9 and precipitates at pH <7
- Never mix with acidic solutions (labetalol, ciprofloxacin, amrinone, milrinone) in the same line
Infusion rate 1:
- Start: 5-10 mg/hour
- Maximum rate: 20 mg/hour (per FDA labeling, though listed as 4 mg/min in some contexts)
- For this 66kg patient, this translates to approximately 0.08-0.15 mg/kg/hour initially
Rationale for Brain Mass Patients
The mechanism of ICP reduction with furosemide is multifactorial 3:
- Decreases CSF production
- Reduces central venous pressure
- Inhibits carbonic anhydrase
- May inhibit astroglial swelling
- Improves cerebral microcirculation
Recent evidence 4 supports combining furosemide with hypertonic saline for ICP control, achieving target ICP <20 mmHg while maintaining plasma sodium 145-155 mmol/L and osmolarity 310-320 mOsmol/kg.
Critical Monitoring Parameters
Immediate (Every 4-6 hours initially)
- Electrolytes: Sodium, potassium, magnesium, chloride
- Renal function: Creatinine, BUN (expect slight creatinine rise during effective diuresis—this is acceptable) 5
- Fluid balance: Hourly urine output, daily weights
- ICP monitoring if available: Target <20 mmHg 4
Daily minimum
- Complete metabolic panel
- Neurological examination
- Volume status assessment (JVP, peripheral edema)
Common Pitfalls and Management
Electrolyte Disturbances
- Hypokalemia: Most common; supplement aggressively to maintain K+ >4.0 mEq/L
- Hypomagnesemia: Often overlooked; check and replace
- Metabolic alkalosis: Expected with loop diuretics; usually well-tolerated
Ototoxicity Risk
- Dose-dependent, especially at rates >4 mg/min for boluses 1
- Higher risk with continuous high-dose infusions
- Monitor for hearing changes or tinnitus
Renal Function
- Mild creatinine elevation (0.3-0.5 mg/dL) during effective diuresis is not an indication to stop therapy 5
- Hold only if creatinine rises >1.0 mg/dL from baseline or GFR falls to <30 mL/min/1.73m²
Drug Interactions
- NSAIDs block diuretic effect—discontinue if possible
- High dietary sodium intake reduces efficacy
- Avoid concurrent nephrotoxic agents
Transition Strategy
When to transition to oral therapy 1:
- ICP controlled and stable
- Patient able to take oral medications
- Hemodynamically stable
- No emergency surgical intervention planned
Conversion: Oral furosemide has ~50% bioavailability
- If infusing 10 mg/hour (240 mg/24 hours), transition to 40-80 mg PO twice daily
- Consider torsemide (better oral bioavailability) at 20-40 mg once daily 6, 5
Special Considerations for Brain Mass Context
Unlike heart failure patients where guidelines emphasize achieving euvolemia 6, the primary goal here is ICP control. This may require more aggressive diuresis than typical volume overload management. The combination of furosemide with hypertonic saline (targeting sodium 145-155 mmol/L) provides superior ICP control compared to furosemide alone 4.
Do not use furosemide as monotherapy—coordinate with neurosurgical team regarding osmotic agents (mannitol, hypertonic saline), head-of-bed elevation, sedation, and potential surgical intervention.